Загрузка...
Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
BACKGROUND: Lubiprostone (8 μg b.d.) received US Food and Drug Administration (FDA) approval in 2008 for the treatment of constipation‐predominant irritable bowel syndrome (IBS‐C) in women aged ≥18 years. In 2012, the FDA issued new guidance for IBS‐C clinical trials, recommending a composite endpoi...
Сохранить в:
| Опубликовано в: : | Aliment Pharmacol Ther |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5215520/ https://ncbi.nlm.nih.gov/pubmed/27669680 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.13807 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|